Vimarsana
Biggest News Aggregation in the World

Page 7 - Immunic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Today - Breaking & Trending Today

Immunic (NASDAQ:IMUX) Coverage Initiated at StockNews.com - Vimarsana News

Immunic (NASDAQ:IMUX) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report sent to investors on Thursday morning. The firm issued a sell rating on the stock. Separately, Wedbush reiterated an outperform rating and issued a $5.00 price objective on shares of Immunic in a report on Tuesday, January 31st. One investment […]

StockNews.com Begins Coverage on Immunic (NASDAQ:IMUX) - Vimarsana News

StockNews.com Begins Coverage on Immunic (NASDAQ:IMUX)

StockNews.com started coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research report report published on Thursday morning. The firm issued a sell rating on the stock. Separately, Wedbush restated an outperform rating and set a $5.00 target price on shares of Immunic in a report on Tuesday, January 31st. One investment analyst […]

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis - Vimarsana News

Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

Immunic, Inc. (NASDAQ:IMUX) Receives $22.00 Consensus PT from Analysts - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Receives $22.00 Consensus PT from Analysts

Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 […]

Source: wkrb13.com
EQS-News: Immunic, Inc.: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis

Issuer: Immunic, Inc. / Key word(s): Scientific publication Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis